RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

被引：0
|
作者：
Ernest Nadal
Hidehito Horinouchi
Jin-Yuan Shih
Kazuhiko Nakagawa
Martin Reck
Edward B. Garon
Yu-Feng Wei
Jens Kollmeier
Bente Frimodt-Moller
Emily Barrett
Olga Lipkovich
Carla Visseren-Grul
Silvia Novello
机构：
[1] Catalan Institute of Oncology,Faculty of Medicine
[2] IDIBELL,Department of Oncology
[3] L’Hospitalet,undefined
[4] National Cancer Center Hospital,undefined
[5] National Taiwan University Hospital,undefined
[6] Kindai University,undefined
[7] LungenClinic,undefined
[8] Airway Research Center North,undefined
[9] German Center for Lung Research,undefined
[10] David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network,undefined
[11] E-Da Cancer Hospital,undefined
[12] I-Shou University,undefined
[13] Helios Klinikum Emil von Behring,undefined
[14] Eli Lilly and Company,undefined
[15] Eli Lilly and Company,undefined
[16] Eli Lilly and Company,undefined
[17] Lilly Oncology,undefined
[18] University of Turin,undefined
[19] A.O.U. San Luigi Gonzaga,undefined
来源：
Drug Safety | 2022年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：45 / 64
页数：19
相关论文
共 50 条
  • [41] Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non-Small-Cell Lung Cancer A Lead-In Study
    Blumenschein, George R., Jr.
    Ciuleanu, Tudor
    Robert, Francisco
    Groen, Harry J. M.
    Usari, Tiziana
    Ruiz-Garcia, Ana
    Tye, Lesley
    Chao, Richard C.
    Juhasz, Erzsebet
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1406 - 1416
  • [42] Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
    Li, Yulin
    Appius, Anita
    Pattipaka, Thirupathi
    Feyereislova, Andrea
    Cassidy, Adrian
    Ganti, Apar Kishor
    PLOS ONE, 2019, 14 (01):
  • [43] Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib
    Inomata, Minehiko
    Hayashi, Ryuji
    Tanaka, Hiroaki
    Shimokawa, Kazuki
    Tokui, Kotaro
    Taka, Chihiro
    Okazawa, Seisuke
    Kambara, Kenta
    Ichikawa, Tomomi
    Yamada, Toru
    Miwa, Toshiro
    Kashii, Tatsuhiko
    Matsui, Shoko
    Tobe, Kazuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (05) : 774 - 778
  • [44] Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
    Zhao, Mengmeng
    Zhang, Jian
    Gao, Jie
    Wang, Jianping
    Ma, Zhenkai
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2025, 14 (01): : 5 - 10
  • [45] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
    Boussageon, Maxime
    Swalduz, Aurelie
    Perol, Maurice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
  • [46] First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring anEGFRmutation
    Landre, Thierry
    Guetz, Gaetan Des
    Chouahnia, Kader
    Duchemann, Boris
    Assie, Jean-Baptiste
    Chouaid, Christos
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (12) : 3333 - 3339
  • [47] Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer
    McCoach, Caroline E.
    Yu, Aiming
    Gandara, David R.
    Riess, Jonathan W.
    Vang, Daniel P.
    Li, Tiahong
    Lara, Primo N.
    Gubens, Matthew
    Lara, Frances
    Mack, Philip C.
    Beckett, Laurel A.
    Kelly, Karen
    JCO PRECISION ONCOLOGY, 2021, 5 : 177 - 190
  • [48] A phase lb trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
    Moran, Teresa
    Palmero, Ramon
    Provencio, Mariano
    Insa, Amelia
    Majem, Margarita
    Reguart, Noemi
    Bosch-Barrera, Joaquim
    Isla, Dolores
    Carcereny Costa, Enric
    Lee, Chooi
    Puig, Marta
    Kraemer, Sandrine
    Schnell, David
    Rosell, Rafael
    LUNG CANCER, 2017, 108 : 154 - 160
  • [49] CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization
    Chooback, Negar
    Lefresne, Shilo
    Lau, Sally C.
    Ho, Cheryl
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (10) : 610 - +
  • [50] PHASE II MULTICENTER TRIAL OF ERLOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Isobe, Kazutoshi
    Homma, Sakae
    Takahashi, Kazuhisa
    Koyama, Ryo
    Mori, Kiyoshi
    Kasai, Takashi
    Tominaga, Shigeru
    Kido, Kenji
    Takaya, Hisashi
    Kishi, Kazuma
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1165 - S1166
12345